Perceptive Advisors NBTX Position
ExitedPerceptive Advisors exited their position in Nanobiotix S.A. (NBTX) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
About Nanobiotix S.A.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Full company profile →Short Interest
0.0%
0.3 days to cover
Perceptive Advisors NBTX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -105,053 | $0 |
| Q1 2025 | Decreased | 105,053 | -161,040 | $376K |
| Q4 2024 | Decreased | 266,093 | -288,973 | $764K |
| Q3 2024 | Held | 555,066 | — | $3.2M |
| Q2 2024 | Held | 555,066 | — | $2.8M |
| Q1 2024 | Held | 555,066 | — | $3.6M |
| Q4 2023 | Held | 555,066 | — | $4.0M |
| Q3 2023 | Decreased | 555,066 | -504,734 | $4.9M |
| Q2 2023 | Held | 1,059,800 | — | $5.4M |
| Q1 2023 | New | 1,059,800 | +1,059,800 | $3.7M |
Frequently Asked Questions
Does Perceptive Advisors own NBTX?
No. Perceptive Advisors exited their position in Nanobiotix S.A. (NBTX) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own NBTX?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in NBTX.
When did Perceptive Advisors first buy NBTX?
Perceptive Advisors's position in NBTX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's NBTX position increasing or decreasing?
Perceptive Advisors completely exited their NBTX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NBTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →